Gastrointestinal issue: Advances in gastrointestinal oncology
Curr Opin Pharmacol. 2024 Feb 23;75:102437. doi: 10.1016/j.coph.2024.102437. Online ahead of print.NO ABSTRACTPMID:38401318 | DOI:10.1016/j.coph.2024.102437 (Source: Current Opinion in Pharmacology)
Source: Current Opinion in Pharmacology - February 24, 2024 Category: Drugs & Pharmacology Authors: Jeroen Dekervel Angelica Petrillo Source Type: research
Targeting the endocannabinoid system for the management of low back pain
Curr Opin Pharmacol. 2024 Feb 23;75:102438. doi: 10.1016/j.coph.2024.102438. Online ahead of print.ABSTRACTLow back pain (LBP) is a major unmet clinical need. The endocannabinoid system (ECS) has emerged as a promising therapeutic target for pain, including LBP. This review examines the evidence for the ECS as a therapeutic target for LBP. While preclinical studies demonstrate the potential of the ECS as a viable therapeutic target, clinical trials have presented conflicting findings. This review underscores the need for innovative LBP treatments and biomarkers and proposes the ECS as a promising avenue for their explorati...
Source: Current Opinion in Pharmacology - February 24, 2024 Category: Drugs & Pharmacology Authors: Mary A Hopkins Brian E McGuire David P Finn Source Type: research
Gastrointestinal issue: Advances in gastrointestinal oncology
Curr Opin Pharmacol. 2024 Feb 23;75:102437. doi: 10.1016/j.coph.2024.102437. Online ahead of print.NO ABSTRACTPMID:38401318 | DOI:10.1016/j.coph.2024.102437 (Source: Current Opinion in Pharmacology)
Source: Current Opinion in Pharmacology - February 24, 2024 Category: Drugs & Pharmacology Authors: Jeroen Dekervel Angelica Petrillo Source Type: research
Targeting the endocannabinoid system for the management of low back pain
Curr Opin Pharmacol. 2024 Feb 23;75:102438. doi: 10.1016/j.coph.2024.102438. Online ahead of print.ABSTRACTLow back pain (LBP) is a major unmet clinical need. The endocannabinoid system (ECS) has emerged as a promising therapeutic target for pain, including LBP. This review examines the evidence for the ECS as a therapeutic target for LBP. While preclinical studies demonstrate the potential of the ECS as a viable therapeutic target, clinical trials have presented conflicting findings. This review underscores the need for innovative LBP treatments and biomarkers and proposes the ECS as a promising avenue for their explorati...
Source: Current Opinion in Pharmacology - February 24, 2024 Category: Drugs & Pharmacology Authors: Mary A Hopkins Brian E McGuire David P Finn Source Type: research
Gastrointestinal issue: Advances in gastrointestinal oncology
Curr Opin Pharmacol. 2024 Feb 23;75:102437. doi: 10.1016/j.coph.2024.102437. Online ahead of print.NO ABSTRACTPMID:38401318 | DOI:10.1016/j.coph.2024.102437 (Source: Current Opinion in Pharmacology)
Source: Current Opinion in Pharmacology - February 24, 2024 Category: Drugs & Pharmacology Authors: Jeroen Dekervel Angelica Petrillo Source Type: research
Editorial overview: Endocrine and metabolic diseases (2023)
Curr Opin Pharmacol. 2024 Jan 29;75:102436. doi: 10.1016/j.coph.2024.102436. Online ahead of print.NO ABSTRACTPMID:38290403 | DOI:10.1016/j.coph.2024.102436 (Source: Current Opinion in Pharmacology)
Source: Current Opinion in Pharmacology - January 30, 2024 Category: Drugs & Pharmacology Authors: Ivana Bjelobaba Stephanie Constantin Source Type: research
Lipid raft disruption as an opportunity for peripheral analgesia
Curr Opin Pharmacol. 2024 Jan 29;75:102432. doi: 10.1016/j.coph.2024.102432. Online ahead of print.ABSTRACTChronic pain conditions are unmet medical needs, since the available drugs, opioids, non-steroidal anti-inflammatory/analgesic drugs and adjuvant analgesics do not provide satisfactory therapeutic effect in a great proportion of patients. Therefore, there is an urgent need to find novel targets and novel therapeutic approaches that differ from classical pharmacological receptor antagonism. Most ion channels and receptors involved in pain sensation and processing such as Transient Receptor Potential ion channels, opioi...
Source: Current Opinion in Pharmacology - January 30, 2024 Category: Drugs & Pharmacology Authors: Andrea Kinga Nehr-Majoros Ágnes Király Zsuzsanna Helyes Éva Szőke Source Type: research
Editorial overview: Endocrine and metabolic diseases (2023)
Curr Opin Pharmacol. 2024 Jan 29;75:102436. doi: 10.1016/j.coph.2024.102436. Online ahead of print.NO ABSTRACTPMID:38290403 | DOI:10.1016/j.coph.2024.102436 (Source: Current Opinion in Pharmacology)
Source: Current Opinion in Pharmacology - January 30, 2024 Category: Drugs & Pharmacology Authors: Ivana Bjelobaba Stephanie Constantin Source Type: research
Lipid raft disruption as an opportunity for peripheral analgesia
Curr Opin Pharmacol. 2024 Jan 29;75:102432. doi: 10.1016/j.coph.2024.102432. Online ahead of print.ABSTRACTChronic pain conditions are unmet medical needs, since the available drugs, opioids, non-steroidal anti-inflammatory/analgesic drugs and adjuvant analgesics do not provide satisfactory therapeutic effect in a great proportion of patients. Therefore, there is an urgent need to find novel targets and novel therapeutic approaches that differ from classical pharmacological receptor antagonism. Most ion channels and receptors involved in pain sensation and processing such as Transient Receptor Potential ion channels, opioi...
Source: Current Opinion in Pharmacology - January 30, 2024 Category: Drugs & Pharmacology Authors: Andrea Kinga Nehr-Majoros Ágnes Király Zsuzsanna Helyes Éva Szőke Source Type: research
Editorial overview: Endocrine and metabolic diseases (2023)
Curr Opin Pharmacol. 2024 Jan 29;75:102436. doi: 10.1016/j.coph.2024.102436. Online ahead of print.NO ABSTRACTPMID:38290403 | DOI:10.1016/j.coph.2024.102436 (Source: Current Opinion in Pharmacology)
Source: Current Opinion in Pharmacology - January 30, 2024 Category: Drugs & Pharmacology Authors: Ivana Bjelobaba Stephanie Constantin Source Type: research
Lipid raft disruption as an opportunity for peripheral analgesia
Curr Opin Pharmacol. 2024 Jan 29;75:102432. doi: 10.1016/j.coph.2024.102432. Online ahead of print.ABSTRACTChronic pain conditions are unmet medical needs, since the available drugs, opioids, non-steroidal anti-inflammatory/analgesic drugs and adjuvant analgesics do not provide satisfactory therapeutic effect in a great proportion of patients. Therefore, there is an urgent need to find novel targets and novel therapeutic approaches that differ from classical pharmacological receptor antagonism. Most ion channels and receptors involved in pain sensation and processing such as Transient Receptor Potential ion channels, opioi...
Source: Current Opinion in Pharmacology - January 30, 2024 Category: Drugs & Pharmacology Authors: Andrea Kinga Nehr-Majoros Ágnes Király Zsuzsanna Helyes Éva Szőke Source Type: research
Editorial overview: Endocrine and metabolic diseases (2023)
Curr Opin Pharmacol. 2024 Jan 29;75:102436. doi: 10.1016/j.coph.2024.102436. Online ahead of print.NO ABSTRACTPMID:38290403 | DOI:10.1016/j.coph.2024.102436 (Source: Current Opinion in Pharmacology)
Source: Current Opinion in Pharmacology - January 30, 2024 Category: Drugs & Pharmacology Authors: Ivana Bjelobaba Stephanie Constantin Source Type: research
Lipid raft disruption as an opportunity for peripheral analgesia
Curr Opin Pharmacol. 2024 Jan 29;75:102432. doi: 10.1016/j.coph.2024.102432. Online ahead of print.ABSTRACTChronic pain conditions are unmet medical needs, since the available drugs, opioids, non-steroidal anti-inflammatory/analgesic drugs and adjuvant analgesics do not provide satisfactory therapeutic effect in a great proportion of patients. Therefore, there is an urgent need to find novel targets and novel therapeutic approaches that differ from classical pharmacological receptor antagonism. Most ion channels and receptors involved in pain sensation and processing such as Transient Receptor Potential ion channels, opioi...
Source: Current Opinion in Pharmacology - January 30, 2024 Category: Drugs & Pharmacology Authors: Andrea Kinga Nehr-Majoros Ágnes Király Zsuzsanna Helyes Éva Szőke Source Type: research
Editorial overview: Endocrine and metabolic diseases (2023)
Curr Opin Pharmacol. 2024 Jan 29;75:102436. doi: 10.1016/j.coph.2024.102436. Online ahead of print.NO ABSTRACTPMID:38290403 | DOI:10.1016/j.coph.2024.102436 (Source: Current Opinion in Pharmacology)
Source: Current Opinion in Pharmacology - January 30, 2024 Category: Drugs & Pharmacology Authors: Ivana Bjelobaba Stephanie Constantin Source Type: research
Lipid raft disruption as an opportunity for peripheral analgesia
Curr Opin Pharmacol. 2024 Jan 29;75:102432. doi: 10.1016/j.coph.2024.102432. Online ahead of print.ABSTRACTChronic pain conditions are unmet medical needs, since the available drugs, opioids, non-steroidal anti-inflammatory/analgesic drugs and adjuvant analgesics do not provide satisfactory therapeutic effect in a great proportion of patients. Therefore, there is an urgent need to find novel targets and novel therapeutic approaches that differ from classical pharmacological receptor antagonism. Most ion channels and receptors involved in pain sensation and processing such as Transient Receptor Potential ion channels, opioi...
Source: Current Opinion in Pharmacology - January 30, 2024 Category: Drugs & Pharmacology Authors: Andrea Kinga Nehr-Majoros Ágnes Király Zsuzsanna Helyes Éva Szőke Source Type: research
